Graphical Abstract
zoster, varicella zoster, coronavirus disease 2019
ZOSTER, VARICELLA ZOSTER, VIRUS, CORONAVIRUS DISEASE 2019, DISEASE, CORONAVIRUS, DISEASE, SEVERE ACUTE RESPIRATORY SYNDROME, INFLUENZA

Accumulating real-world data substantiate the protective benefits of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines and the need for additional doses beyond the primary series due to waning immunity and/or emergence of new variants [Numerous health agencies including the United States (US) Centers for Disease Control and Prevention (CDC) have recommended, in the absence of specific contraindications, administration of COVID-19 booster vaccines on the same day as other vaccines [When addressing coadministration of COVID-19 vaccines with other vaccines, the CDC recommends to consider the reactogenicity profile of the vaccines. The CDC notes that it is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, particularly with vaccines known to be more reactogenic, such as adjuvanted vaccines [The adjuvanted recombinant zoster vaccine (RZV; Shingrix, GSK) is a non-live subunit vaccine that contains the varicella zoster virus glycoprotein E (gE) as the active ingredient, together with the liposome-based adjuvant system AS01Moderna's COVID-19 vaccine, mRNA-1273, is an mRNA-based vaccine encapsulated in a lipid nanoparticle. The vaccine includes a single mRNA sequence encoding the prefusion stabilized spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Wuhan strain. Two doses of 100 µg mRNA-1273, as a primary series, showed 94.1% efficacy at preventing COVID-19, including severe disease [Although coadministration with RZV is not contraindicated, no clinical trial data are available on its coadministration with COVID-19 vaccines. To address this data gap and provide evidence-based guidance for healthcare providers making decisions on such vaccine coadministrations, we conducted a clinical trial to assess the safety and immunogenicity of coadministration of a booster dose (50 µg) of mRNA-1273 with either seasonal quadrivalent influenza vaccine in adults aged ≥18 years, or RZV in adults aged ≥50 years. The results of coadministration of RZV and mRNA-1273 are reported here.